7,180,897 Shares in Immunovant, Inc. $IMVT Acquired by BlackRock Inc.

Posted by George Bondi on Aug 27th, 2026

BlackRock Inc. bought a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the second quarter, Holdings Channel reports. The fund bought 7,180,897 shares of the company’s stock, valued at approximately $276,680,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Immunovant by 8.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock worth $708,000 after purchasing an additional 3,348 shares during the period. Goldman Sachs Group Inc. increased its holdings in Immunovant by 48.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock valued at $17,222,000 after purchasing an additional 329,354 shares during the period. Strs Ohio bought a new position in Immunovant during the 1st quarter worth $27,000. Legal & General Group Plc raised its position in Immunovant by 6.9% during the 2nd quarter. Legal & General Group Plc now owns 77,296 shares of the company’s stock worth $1,237,000 after purchasing an additional 5,010 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in Immunovant by 20.7% during the 2nd quarter. Invesco Ltd. now owns 66,750 shares of the company’s stock worth $1,068,000 after buying an additional 11,438 shares during the period. 47.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Immunovant news, CEO Eric Venker sold 3,092 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $38.48, for a total value of $118,980.16. Following the transaction, the chief executive officer directly owned 254,280 shares of the company’s stock, valued at approximately $9,784,694.40. The trade was a 1.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Melanie Gloria sold 2,036 shares of the stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $39.55, for a total value of $80,523.80. Following the transaction, the chief operating officer owned 222,357 shares in the company, valued at $8,794,219.35. The trade was a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 96,859 shares of company stock valued at $3,720,588 in the last 90 days. Company insiders own 1.90% of the company’s stock.

Immunovant Trading Up 0.9%

Shares of IMVT opened at $43.89 on Thursday. The firm’s fifty day simple moving average is $40.00 and its two-hundred day simple moving average is $32.18. Immunovant, Inc. has a 12 month low of $14.47 and a 12 month high of $45.42. The stock has a market capitalization of $9.07 billion, a P/E ratio of -15.56 and a beta of 0.77.

Immunovant (NASDAQ:IMVT – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12). The firm had revenue of $7.09 million during the quarter, compared to the consensus estimate of $7.09 million. During the same quarter last year, the company earned ($0.71) earnings per share. As a group, research analysts predict that Immunovant, Inc. will post -2.9 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. upped their price target on Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Citigroup raised their price objective on Immunovant from $57.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Truist Financial lifted their price objective on Immunovant from $23.00 to $30.00 and gave the stock a “hold” rating in a research note on Friday, May 22nd. HC Wainwright upped their target price on Immunovant from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Immunovant in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Immunovant has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Read Our Latest Stock Report on Immunovant

Immunovant Company Profile

(Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.